{
    "title": "Biogen leans on new Alzheimer's drug to calm investor worries",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11031709/Biogen-profit-doubles-Samsung-Bioepis-stake-sale.html",
    "date": "2022-07-20",
    "keywords": [
        "biogen",
        "aduhelm",
        "treatment",
        "profit",
        "share",
        "plan",
        "drug",
        "sclerosis",
        "boston",
        "lecanemab",
        "drugmaker",
        "approval",
        "forecast",
        "analyst",
        "raymond",
        "reporting",
        "inc",
        "wednesday",
        "investor",
        "co",
        "ltd",
        "promising",
        "lawsuit",
        "case",
        "trial",
        "week",
        "growth",
        "competition",
        "blockbuster",
        "tecfidera",
        "fall",
        "eisai",
        "regulator",
        "deadline",
        "launch",
        "phase",
        "commercialization",
        "officer",
        "michael",
        "mcdonnell",
        "june",
        "government",
        "health",
        "age",
        "use",
        "efficacy",
        "sale",
        "quarter",
        "upside",
        "legacy",
        "sandler",
        "christopher",
        "range",
        "program",
        "wedbush",
        "laura",
        "chico",
        "editing",
        "david",
        "gregorio"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}